GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » Return-on-Tangible-Asset

Elanco Animal Health (Elanco Animal Health) Return-on-Tangible-Asset : -11.58% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Elanco Animal Health Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Elanco Animal Health's annualized Net Income for the quarter that ended in Dec. 2023 was $-564 Mil. Elanco Animal Health's average total tangible assets for the quarter that ended in Dec. 2023 was $4,871 Mil. Therefore, Elanco Animal Health's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -11.58%.

The historical rank and industry rank for Elanco Animal Health's Return-on-Tangible-Asset or its related term are showing as below:

ELAN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -26.11   Med: -5.76   Max: 2.55
Current: -25.23

During the past 9 years, Elanco Animal Health's highest Return-on-Tangible-Asset was 2.55%. The lowest was -26.11%. And the median was -5.76%.

ELAN's Return-on-Tangible-Asset is ranked worse than
78.02% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs ELAN: -25.23

Elanco Animal Health Return-on-Tangible-Asset Historical Data

The historical data trend for Elanco Animal Health's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanco Animal Health Return-on-Tangible-Asset Chart

Elanco Animal Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only 1.94 -13.36 -9.86 -1.66 -26.11

Elanco Animal Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.74 8.61 -7.76 -87.29 -11.58

Competitive Comparison of Elanco Animal Health's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elanco Animal Health's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Elanco Animal Health's Return-on-Tangible-Asset falls into.



Elanco Animal Health Return-on-Tangible-Asset Calculation

Elanco Animal Health's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-1231/( (4656+4774)/ 2 )
=-1231/4715
=-26.11 %

Elanco Animal Health's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-564/( (4967+4774)/ 2 )
=-564/4870.5
=-11.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Elanco Animal Health  (NYSE:ELAN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Elanco Animal Health Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanco Animal Health (Elanco Animal Health) Business Description

Traded in Other Exchanges
Address
2500 Innovation Way, Greenfield, IN, USA, 46140
Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Executives
Grace Mcardle officer: EVP, MANUFACTURING AND QUALITY 2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington officer: See remarks C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
R David Hoover director C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Jeffrey N Simmons director, officer: Pres., Chief Executive Officer 2500 INNOVATION WAY, GREENFIELD IN 46140
John P Bilbrey director
Rajeev A. Modi officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen director C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Michael J Harrington director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Brabander Ellen De officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger officer: Ex VP, Gen Counsel & Corp Sec C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia director 11690 N.W. 105TH STREET, MIAMI FL 33178
William F Doyle director
Uncas Gp Llc director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Capital Management Lp director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Scott D. Ferguson director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019